ADCs Advances: Transforming Breast Cancer Care Today and Beyond

This OncLive News Network series examines the expanding role of antibody drug conjugates (ADCs) in the treatment of breast cancer. Experts Paolo Tarantino, MD and Jason Aboudi Mouabbi, MD review key data from ESMO 2025 and describe how ADCs are influencing care across HER2 positive, HER2 low, hormone receptor positive, and triple negative disease. The faculty outline major findings from DESTINY Breast05, DESTINY Breast11, TROPION Breast02, and ASCENT03, emphasizing how trastuzumab deruxtecan, datopotamab deruxtecan, and sacituzumab govitecan are moving into both early and metastatic settings. The discussion highlights clinical considerations such as patient selection, biomarkers, and the influence of brain involvement or early relapse on treatment choice. The experts review safety profiles, supportive care needs, and practical issues related to infusion planning and monitoring. The series concludes with emerging strategies that include combination therapy, next generation targets, and research priorities that will shape future use of ADCs in breast cancer.